Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15136MR)

This product GTTS-WQ15136MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases, Pemphigus vulgaris (PV) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15136MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9657MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ5989MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ1415MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ9096MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ676MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ4607MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ3256MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ2804MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW